FDA Releases Draft Guidance On CMC For Individualized ASO Therapies
A new FDA guidance released in Dec. 2021 acknowledges the difficulties inherent in manufacturing individualized antisense oligonucleotide (ASO)...
Source: pharmaceuticalonline.com